Research Library

Twenty-eight point seven percent. That was the average percentage of body weight lost by participants who received the highest dose of retatrutide in the TRIUMPH-4 study, the largest Phase 3 clinical trial ever conducted with a triagonist. For context: no medication had reached this in a controlled Phase 3 study. Not Ozempic. Not Mounjaro. None.

The War Inside Every Cell, and NAD+ in the Crossfire

In the hypothalamus, less than two centimeters from the geometric center of the brain, there is a small group of neurons that functions like a clock. They fire in pulses. And each pulse decides whether the body will, or will not, sustain reproduction.

For decades, growth hormone was studied only to treat children with deficiency. Today, researchers see it as one of the most underestimated keys to adult biology, and GHRH analogs as the tool that may, finally, open that door.

The scientific story of how two researchers created a class of molecules with intrinsic mitochondrial selectivity, and why that discovery took two decades to be taken seriously by the pharmaceutical world.

For decades, conventional medicine had no effective pharmacological answer for fatty liver disease, a condition that affects an estimated 25% of the world’s adult population and that, in its more advanced forms, can lead to cirrhosis and transplant.